Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares Repurchased
Ratios

Utah Medical Products (UTMD) Accumulated Depreciation & Amortization (2016 - 2025)

Utah Medical Products has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $25.3 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $25.3 million for Q4 2025, up 5.91% from a year ago — trailing twelve months through Dec 2025 was $25.3 million (up 5.91% YoY), and the annual figure for FY2025 was $25.3 million, up 5.91%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $25.3 million at Utah Medical Products, up from $23.9 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for UTMD hit a ceiling of $25.3 million in Q4 2025 and a floor of $22.8 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $23.7 million (2023), compared with a mean of $23.7 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 0.62% in 2022 and later rose 5.91% in 2025.
  • Utah Medical Products' Accumulated Depreciation & Amortization stood at $22.8 million in 2021, then rose by 0.62% to $22.9 million in 2022, then rose by 3.39% to $23.7 million in 2023, then rose by 0.86% to $23.9 million in 2024, then rose by 5.91% to $25.3 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $25.3 million (Q4 2025), $23.9 million (Q4 2024), and $23.7 million (Q4 2023) per Business Quant data.